HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Lamisil One-Week Cure Ad Claims Substantiated - NAD

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health's Lamisil AT "cures with just one week's use" advertising claim for the treatment of athlete's foot is not likely to mislead consumers, the National Advertising Division of the Council of Better Business Bureaus determined.

You may also be interested in...

Lotrimin Ultra Antifungal Switch Approved By FDA

Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name

Novartis Desenex Max Supported With Comparative TV Ads, FSIs

The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts